Mr. Dennis Hancock reports

MOUNTAIN VALLEY MD ANNOUNCES PUBLICATION OF SOLUVEC TRIAL DATA IN THERAPEUTIC DELIVERY

Mountain Valley MD Holdings Inc.'s Soluvec study data have recently been peer reviewed and published in the journal Therapeutic Delivery. The published study highlights the benefits of the company's patented Soluvec formulation, a novel, solvent-free aqueous ivermectin invention. This proprietary Soluvec formulation was developed using the company's patented Quicksol solubilization technology, which aims to address the poor solubility challenges associated with ivermectin and potentially other macrocyclic lactones.

The study confirmed that parenteral administration of Soluvec led to an ivermectin drug exposure approximately seven times higher than traditional oral drug dosing, with greater bioavailability, offering potential for enhanced therapeutic effectiveness.

Key findings from the study:

• Improved solubility with Soluvec: In the resolubilized product, Soluvec, ivermectin was present as a mix of 28.0-nanometre particles and polysorbate-solubilized-free ivermectin. The total concentration was approximately 2,500 times greater than that of free ivermectin in water.
• IVM exposure seven times higher: In beagle dogs treated parenterally with Soluvec (subcutaneous or intramuscular dosing), total exposure of ivermectin was approximately seven times higher than in dogs receiving a non-solubilized ivermectin tablet of the same dose orally.
• Increased duration of exposure: Peak levels were higher, and, most importantly for ease of treatment, duration of exposure was reliably greater with parenteral dosing. All Soluvec-treated animals had detectable IVM at 48 h, versus none of the non-solublized ivermectin orally dosed animals.
• Lower doses possible: Enhanced bioavailability of IVM in Soluvec suggests that a lower dose may achieve the desired therapeutic effects, potentially leading to reduced treatment costs and fewer side effects.
• Safety profile: Research underscores favourable safety profile of Soluvec, with minimal side effects generally observed in test subjects.
• Potential human and livestock applications: The results point to the possibility of easier treatment regimens and improved therapeutic outcomes not just for livestock but potentially for humans as well.

"MVMD deems this research as particularly significant given our belief, and what is common knowledge among scientists, that the poor solubility of the avermectin drug class (a series of drugs and pesticides used to treat parasitic worms and insect pests) remains a barrier to achieving and maintaining therapeutic drug levels in humans and livestock species," stated Dennis Hancock, president and chief executive officer of Mountain Valley. "As outlined in the publication, it is likely this challenge will continue for the coming decade and may worsen with stronger drug resistance becoming the reality. Conventional ivermectin formulations simply have not been able to achieve and maintain therapeutic drug levels, compromising the effectiveness of treatments."

The article, titled "Physical and pharmacokinetic characterization of Soluvec, a novel, solvent-free aqueous ivermectin formulation," is available on-line ahead of print production.

"The peer review process for consideration of publication of MVMD's study is a third party validation of our science and the potential commercial efficacy of our Soluvec product," continued Mr. Hancock. "I am very proud of our science team for this accomplishment and look forward to the pending product rollout we anticipate this year in the animal husbandry industry in Bangladesh."

On May 8, 2023, the company announced it had entered into a licensing and manufacturing licence agreement with a privately held Ontario corporation for its Soluvec 1-per-cent animal husbandry applications for the territory of the People's Republic of Bangladesh.

Quicksol is the company's patented solubilization technology, which has been developed to provide solubilized drug delivery options across the macrocyclic lactone class of anti-parasitic drugs and is the principal technology applied to Soluvec.

To safeguard its intellectual property and the company's licensing royalty model, Mountain Valley has filed for its principal Quicksol patent protection. These filings target key markets that the company has deemed strategically important at this time where it is anticipated its Soluvec products will be sold in the future. In April, 2023, Mountain Valley had filed for Soluvec protection in 12 additional markets outside of the United States, including Canada, China, India, Mexico, Sri Lanka, Thailand, Philippines, Malaysia, Brazil, Peru, Argentina and Chile.

About Mountain Valley MD Holdings Inc.

Mountain Valley is building a world-class organization centred around the implementation, licensing and reselling of key technologies and formulations:

• Patented Quicksome oral formulation and delivery technologies;
• Patented Quicksol solubility formulation technology;
• Licensed product reseller of Agrarius, a novel agricultural-plant-signalling technology.

Consistent with its vision toward more life, Mountain Valley applies its owned and licensed technologies to its work for advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety and more. Additionally, Mountain Valley's work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage.

Mountain Valley's patented Quicksome technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster and with greater impact, efficiency and accuracy.

Mountain Valley's patented Quicksol technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally.

Mountain Valley's licensed Agrairus agricultural plant signalling technology that could be capable of application to agricultural crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change.

We seek Safe Harbor.